Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd

Shanghai Stock Exchange 603707.SS

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd EBITDA Margin for the year ending December 31, 2023: -1.47%

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd EBITDA Margin is -1.47% for the year ending December 31, 2023, a -104.01% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd EBITDA Margin for the year ending December 31, 2022 was 36.71%, a -2.44% change year over year.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd EBITDA Margin for the year ending December 31, 2021 was 37.63%, a 3.71% change year over year.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd EBITDA Margin for the year ending December 31, 2020 was 36.29%, a 20.15% change year over year.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd EBITDA Margin for the year ending December 31, 2019 was 30.20%, a -0.63% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Shanghai Stock Exchange: 603707.SS

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd

CEO	Ms. Wu Guiping
IPO Date	July 19, 2017
Location	China
Headquarters	1/16 Nanjing Jiangbei New
Employees	1,451
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd manufactures and sells heparin sodium and low molecular weight heparin products for pharmaceutical companies in the People's Republic of China. It offers enoxaparin sodium, dalteparin sodium, and naqu heparin calcium injections. The company also exports its products primarily to the European and American countries. The company was founded in 2000 and is based in Nanjing, the People's Republic of China.

Key trends

Past 5 years